Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.59 |
| ▸ | PPARG | P37231 | 2/20 | 0.59 |
| ▸ | FABP2 | P12104 | 1/20 | 0.59 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13983880 | 0.90 | PPARA (0.48) | PPARAPPARGFABP2SLC22A12CNR1 | |
| SCHEMBL11260925 | 0.87 | PPARA (0.65) | PPARAPPARGFABP2SLC22A12CNR1 | |
| SCHEMBL22221537 | 0.81 | PPARA (0.68) | PPARAPPARGFABP2SLC22A12CNR1 | |
| SCHEMBL22209082 | 0.80 | PPARA (0.70) | PPARAPPARGFABP2SLC22A12CNR1 | |
| SCHEMBL12573663 | 0.80 | PPARA (0.70) | PPARAPPARGFABP2SLC22A12CNR1 | |
| SCHEMBL12634744 | 0.80 | PPARA (0.74) | PPARAPPARGFABP2SLC22A12CNR1 | |
| SCHEMBL22221524 | 0.79 | PPARA (0.68) | PPARAPPARGFABP2SLC22A12CNR1 | |
| SCHEMBL4756720 | 0.79 | PPARA (0.60) | PPARAPPARGFABP2SLC22A12CNR1 | |
| SCHEMBL13984064 | 0.78 | PPARA (0.53) | PPARAPPARGFABP2SLC22A12CNR1 | |
| SCHEMBL22221587 | 0.76 | PPARA (0.65) | PPARAPPARGFABP2SLC22A12CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008157537-A2 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | LIPC, PNLIP, LIPA | PPARA 93/4885PPARG 104/4885FABP2 51/4885 |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | LIPC, PNLIP, LIPA | PPARA 93/4885PPARG 104/4885FABP2 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.